Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

THRD

Third Harmonic Bio Inc

Dec 05 • 04:00PM ET

9.43

Dollar change -0.07
Percentage change -0.74	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	61.32%	Shs Outstand	39.38M	Perf Week	21.68%
Market Cap	374.65M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	0.00%	Shs Float	15.37M	Perf Month	44.85%
Income	-35.48M	PEG	-	EPS next Q	-0.31	Inst Own	47.07%	Short Float / Ratio	12.60% / 13.57	Perf Quarter	56.91%
Sales	0.00M	P/S	-	EPS this Y	57.63%	Inst Trans	-	Short Interest	1.94M	Perf Half Y	87.48%
Book/sh	6.87	P/B	1.37	EPS next Y	-24.77%	ROA	-12.09%	Target Price	7.00	Perf Year	-55.07%
Cash/sh	6.89	P/C	1.37	EPS next 5Y	-	ROE	-12.42%	52W Range	3.75 - 23.42	Perf YTD	119.30%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-12.84%	52W High	-59.74%	Beta	3.26
Dividend %	-	Quick Ratio	47.00	Sales past 5Y	0.00%	Gross Margin	-	52W Low	151.47%	ATR	0.66
Employees	28	Current Ratio	47.00	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	80.28	Volatility	12.77% 7.58%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	11.44%	Profit Margin	-	Rel Volume	11.38	Prev Close	9.50
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 09 BMO	Payout	-	Avg Volume	142.65K	Price	9.43
Recom	2.00	SMA20	33.16%	SMA50	38.54%	SMA200	69.20%	Volume	1,622,762	Change	-0.74%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-22	Downgrade	Jefferies	Buy → Hold	$30 → $3.60
Dec-15-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$5
Oct-10-22	Initiated	Morgan Stanley	Overweight	$34
Oct-10-22	Initiated	Jefferies	Buy	$30
Oct-10-22	Initiated	Cowen	Outperform

Nov-09-23 09:30AM	Third Harmonic Bio Inc (THRD) Reports Q3 2023 Financial Results and Continues Progress Towards ... (GuruFocus.com)
08:30AM	Third Harmonic Bio Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 08:30AM	Third Harmonic Bio Announces Leadership Changes (GlobeNewswire) -9.22%
Aug-31-23 08:30AM	Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-10-23 08:10AM	Third Harmonic Bio Announces Second Quarter 2023 Financial Results (GlobeNewswire) -7.00%
09:40AM	Loading…
Jul-26-23 09:40AM	Target downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly) +9.11%
Jul-25-23 08:30AM	Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 (GlobeNewswire) +5.26%
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-24-23 11:02AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
May-11-23 05:00PM	Third Harmonic Bio Announces First Quarter 2023 Financial Results (GlobeNewswire) -7.32%
Mar-29-23 08:05AM	Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results (GlobeNewswire)
Dec-23-22 06:32AM	Daily Vickers Top Buyers & Sellers for 12/23/2022 (Argus Research)
Dec-22-22 05:41AM	The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug (American City Business Journals)
Dec-15-22 10:10AM	Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety Concerns (Benzinga) -78.28%
09:53AM	Third Harmonic Plunges Almost 80% After Ending Study for Skin-Inflammation Drug (Bloomberg)
08:49AM	Loading…
08:49AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
08:22AM	Third Harmonic's stock falls 75% after discontinuing clinical trial (MarketWatch)
07:00AM	Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria (GlobeNewswire)
Nov-21-22 04:05PM	Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-22 04:15PM	Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 08:01AM	These Bases, Breakouts And Buy Zones Offer Fresh Opportunities (Investor's Business Daily) -6.14%
Sep-19-22 04:10PM	Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.56%
Sep-15-22 11:41AM	Third Harmonic Bio stock opens more than 20% above IPO price (MarketWatch)
07:58AM	Third Harmonic Bio prices upsized IPO at $17 a share, midpoint of range (MarketWatch)

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BVF PARTNERS L P/IL	10% Owner	Dec 20	Buy	4.11	214,063	879,499	2,332,638	Dec 22 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

THRD

Third Harmonic Bio Inc

Upgrade your FINVIZ experience